Analysts Are Downgrading These 5 Pharmaceutical Stocks

Page 1 of 5

In this article, we present the 5 pharmaceutical stocks that are being downgraded by analysts. If you want to read our comprehensive analysis of the pharmaceutical industry, go directly to Analysts Are Downgrading These 10 Pharmaceutical Stocks.

5. DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

Number of Hedge Fund Holders: 28

Although it’s not a pure pharma play, Dentsply Sirona makes dental equipment and specializes in anesthetics, plaque and gum disease prevention (prophylaxis) and tooth polishers. The stock is down about 13% after Piper Sandler analyst Jason Bednar downgraded Dentsply Sirona to Neutral from Overweight with a price target of $46, down from $71. The analyst highlighted the weak Q1 results and the sudden departure of CEO Don Casey for the downgrade.

Page 1 of 5